Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Asthenopia
- Sponsor
- Namyi Gu
- Enrollment
- 60
- Primary Endpoint
- Change of the modified questionnaire scores proposed by Ames et al.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Asthenopia or eye strain describes nonspecific symptoms of an eye when it is tired from intensive work. Vaccinium uliginosum is a flowering plant in the genus Vaccinium. This plant is native to cool temperature regions of the Northern Hemisphere. Considering its antioxidative ingredients, the extract of Vaccinium uliginosum is expected to play a significant role in treating various ocular pathologies. The investigators performed a randomized, case-controlled study in healthy subjects and investigated the protective effect of Vaccinium uliginosum extract (DA-9301) on tablet computer-induced asthenopia.
Investigators
Namyi Gu
Assistant professor
DongGuk University
Eligibility Criteria
Inclusion Criteria
- •Healthy subject aged 20 to 65 years with more than 2 hours of daily use of a smart phone or computer including a tablet and television
Exclusion Criteria
- •Ocular disease in either eye
- •Ocular surface disease
- •Best corrected visual acuity \< 20/30
- •Intraocular pressure \> 21 mmHg
- •Optical coherence tomography proven retinal nerve fiber defect
- •Significant cataract (lens opacities classification system III)
- •Significant entropion or ectropion
- •Significant tear drainage problem proved with fluorescein dye dilution test
- •Soft or Hard contact lens use 3 or more days a week
- •History of oral intake of health supplement designed to improve asthenopia within 4 weeks before participating this study
Outcomes
Primary Outcomes
Change of the modified questionnaire scores proposed by Ames et al.
Time Frame: before and immediately after tablet computer use on Day 0 and Day 29 (deviation window: Day 21-31)